Meeting Banner
Abstract #1523

Diagnostic Value of R2* in Identifying ALK Mutations in Transgenic Murine Models of Neuroblastoma

Laura Glass1, 2, Yann Jamin1, Rani George3, Louis Chesler2, Simon P. Robinson1

1CRUK and ESPRC Cancer Imaging Centre, The Institute of Cancer Research, Sutton, London, United Kingdom; 2Paediatric Oncology, The Institute of Cancer Research, Sutton, London, United Kingdom; 3Pediatric Oncology, Harvard University School of Medicine, Dana Faber Cancer Institute, Boston, MA, United States


Neuroblastoma is the most common extra-cranial solid tumour of infancy. It is well established that MCYN amplified patients are strongly correlated with a poor prognosis and increased likelihood of disease relapse. More recently, patients with ALK mutated cases of neuroblastoma have been associated with a very poor prognosis and an ultra-high risk of disease relapse. This study uses R2* to identify the presence of an ALK mutation in transgenic murine models. If this phenomenon translates to clinical situation, multi-gradient echo sequences could be incorporated into diagnostic scanning in neuroblastoma to stratify patients for targeted therapy.

Keywords